Company profile
Inovio Pharmaceuticals, Inc.
Pipeline6 assets
- INO-3107INO-3107 / HPV-6 and HPV-11 / DNA immunotherapy / HPV-related rare diseaseRecurrent Respiratory Papillomatosis (RRP) in adultsBLA accepted under accelerated approval, PDUFA Oct 30 2026United States
- VGX-3100VGX-3100 / HPV-16/18 / DNA immunotherapy / HPV-related diseasesCervical dysplasia (HSIL)3Ongoing (partnered)ChinaAnal dysplasia
- INO-3112INO-3112 / HPV-16/18 / DNA immunotherapy / OncologyHPV16/18-positive oropharyngeal squamous cell carcinoma (OPSCC)3Phase 3 planningUnited StatesEurope
- INO-5401INO-5401 / Tumor-associated antigens / DNA immunotherapy / OncologyGlioblastoma (GBM)1Ongoing Phase 1; Phase 2 planning (as INO-5412 w/ Akeso)United StatesPrevention in BRCA1/2 mutation carriers1Ongoing Phase 1United States
- INO-4201INO-4201 / Ebola virus / DNA medicine / Infectious diseasesEbola vaccine booster (to ERVEBO)2Phase 2 planning; Phase 1b completed
- DMAb SARS-CoV-2SARS-CoV-2 / DNA-encoded monoclonal antibody / Infectious diseasesSARS-CoV-21Ongoing Phase 1; data expected/reportedUnited States